HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Perspective
When a natural disaster or emergency strikes, where is one of the first places people turn to? Their local hospital.That’s because hospitals and health systems…
Headline
Baxter announced that it is increasing the current U.S. allocation levels of its highest-demand IV fluids for direct customers from 40% to 60%, and for…
Headline
AHA President and CEO Rick Pollack Oct. 7 sent a letter to President Biden urging the Administration to take immediate actions to increase the supply of IV…
Headline
The Department of Health and Human Services Sept. 30 released a statement on the dockworker strike at ports along the East and Gulf coasts, saying that…
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…